These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1079 related items for PubMed ID: 24195574

  • 1. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [Abstract] [Full Text] [Related]

  • 2. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

  • 3. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.
    Curr Med Res Opin; 2012 May 01; 28(5):767-80. PubMed ID: 22462530
    [Abstract] [Full Text] [Related]

  • 4. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
    Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, Foschi M, Filippini G, Tramacere I, Baldin E, Nonino F.
    Cochrane Database Syst Rev; 2024 Jan 04; 1(1):CD011381. PubMed ID: 38174776
    [Abstract] [Full Text] [Related]

  • 5. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 6. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.
    Cochrane Database Syst Rev; 2013 Jun 06; 2013(6):CD008933. PubMed ID: 23744561
    [Abstract] [Full Text] [Related]

  • 7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2014 Jul 26; (7):CD009333. PubMed ID: 25062935
    [Abstract] [Full Text] [Related]

  • 8. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 9. New management algorithms in multiple sclerosis.
    Sorensen PS.
    Curr Opin Neurol; 2014 Jun 24; 27(3):246-59. PubMed ID: 24759080
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M.
    Mult Scler Relat Disord; 2016 Sep 24; 9():23-30. PubMed ID: 27645339
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun 24; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H, Hu F, Zhang Y, Li K.
    J Neurol; 2020 Dec 24; 267(12):3489-3498. PubMed ID: 31129710
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons.
    Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M.
    Ther Adv Neurol Disord; 2024 Dec 24; 17():17562864241237856. PubMed ID: 38855023
    [Abstract] [Full Text] [Related]

  • 19. Dimethyl fumarate for multiple sclerosis.
    Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.
    Cochrane Database Syst Rev; 2015 Apr 22; 2015(4):CD011076. PubMed ID: 25900414
    [Abstract] [Full Text] [Related]

  • 20. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C, Aloi JJ.
    Clin Ther; 2015 Apr 01; 37(4):691-715. PubMed ID: 25846320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.